New Advances in Molecular Breast Cancer Pathology

• Published in: Seminars in cancer biology Vol. 72; pp. 102 - 113
• Main Authors: Rakha, Emad A., Pareja, Fresia G.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.07.2021
• Subjects: Biomarkers, Tumor - genetics; Breast cancer; Breast Neoplasms - classification; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Female; Gene Expression Profiling; Humans; Molecular prognostic assays; Molecular taxonomy; Mutational signatures; Next generation sequencing; Pathology, Molecular - methods; Precision Medicine; Prognosis; Molecular prognostic assays; Breast cancer; Mutational signatures; Gene expression profiling; Next generation sequencing; Molecular taxonomy
• ISSN: 1044-579X; 1096-3650
• DOI: 10.1016/j.semcancer.2020.03.014

Breast cancer (BC) comprises a diverse spectrum of diseases featuring distinct presentation, morphological, biological, and clinical phenotypes. BC behaviour and response to therapy also vary widely. Current evidence indicates that traditional prognostic and predictive classification systems are insufficient to reflect the biological and clinical heterogeneity of BC. Advancements in high-throughput molecular techniques and bioinformatics have contributed to the improved understanding of BC biology, refinement of molecular taxonomies and the development of novel prognostic and predictive molecular assays. Molecular testing has also become increasingly important in the diagnosis and treatment of BC in the era of precision medicine. Despite the enormous amount of research work to develop and refine BC molecular prognostic and predictive assays, it is still in evolution and proper incorporation of these molecular tests into clinical practice to guide patient’s management remains a challenge. With the increasing use of more sophisticated high throughput molecular techniques, large amounts of data will continue to emerge, which could potentially lead to identification of novel therapeutic targets and allow more precise classification systems that can accurately predict outcome and response to therapy. In this review, we provide an update on the molecular classification of BC and molecular prognostic assays. Companion diagnostics, contribution of massive parallel sequencing and the use of liquid biopsy are also highlighted.